Bristol Myers Squibb has turned to the source of Leqembi to further its push into Alzheimer’s disease, paying BioArctic $100 ...

Bristol Myers Squibb acquires global rights to BioArctic’s Alzheimer’s antibody candidates BAN1503 and BAN2803 for up to $1.3 ...

China's medical regulator has approved Eli Lilly's treatment for early Alzheimer's, providing patients with another option ...

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that it has entered into a global exclusive license agreement with Bristol ...

The summary highlights significant activities in the health sector, including Eli Lilly's Alzheimer's treatment approval in ...

This move diversifies options for patients following the earlier approval of Eisai and Biogen's Leqembi in January. CVS faces ...

Vertex Pharmaceuticals reported that its non-opioid drug reduced back pain significantly. But Vertex stock plunged as a ...

It’s important to connect with loved ones this time of year but when Alzheimer’s is in the mix, it can be extra stressful.

Shutdown Grows Closer as Trump Tells G.O.P. to Kill Spending Deal The bill Republicans and Democrats agreed on is in jeopardy after President-elect Trump condemned it three days before the ...

December 18, 2024 • At a federal prison in rural Virginia, more than 50 prisoners say they've been abused. But when they try to file a complaint — they're stopped, often by the same guards ...